Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:May 1, 2015

Use our guide to learn which trials are right for you!

A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

This phase II trial studies how well nivolumab with or without ipilimumab works in treating
patients with anal canal cancer that has not responded to previous treatment (refractory) and
has spread to other places in the body (metastatic). Immunotherapy with monoclonal
antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread.

PRIMARY OBJECTIVES:

I. To evaluate overall response rate (ORR) with nivolumab in patients with previously treated
metastatic squamous cell carcinoma (SCCA) of the anal canal. (Part A) II. To determine an
improvement in progression-free survival (PFS) when nivolumab is combined with ipilimumab
versus (vs.) nivolumab alone in patients with previously treated metastatic SCCA (Part B).

SECONDARY OBJECTIVES:

I. To evaluate progression-free survival (PFS) of nivolumab in patients with previously
treated metastatic SCCA of the anal canal. (Part A) II. To evaluate overall survival (OS) in
patients with previously treated metastatic SCCA of the anal canal treated with nivolumab.
(Part A) III. To evaluate the grade 3 and 4 toxicity rate in patients with previously treated
metastatic SCCA of the anal canal when treated with nivolumab. (Part A) IV. To evaluate the
overall response rate (ORR) of nivolumab plus or minus ipilimumab in patients with previously
treated metastatic SCCA of the anal canal. (Part B) V. To evaluate overall survival (OS) in
patients with previously treated metastatic SCCA of the anal canal treated with nivolumab
plus or minus ipilimumab. (Part B) VI. To evaluate the grade 3 and 4 toxicity rate in
patients with previously treated metastatic SCCA of the anal canal when treated with
nivolumab plus or minus ipilimumab. (Part B)

EXPLORATORY OBJECTIVES:

I. To evaluate ORR, PFS, and OS based on expression of programmed cell death 1 ligand 1
(PD-L1), programmed cell death 1 (PD-1), peritumoral cluster of differentiation (CD)8+ tumor
infiltrating lymphocytes (TILs), peritumoral CD4+ TILs, and regulatory T cells as analyzed
from tumor biopsies in previously treated patients with metastatic SCCA of the anal canal
when treated with nivolumab. (Part A) II. To evaluate radiographic responses according to
relative changes in proportions of anti-human papillomavirus (HPV) specific CD8+ and CD4+
TILs and regulatory T cells in patients with previously treated metastatic SCCA of the anal
canal following treatment with nivolumab, analyzed from serial peripheral blood samples.
(Part A) III. To evaluate ORR, PFS, and OS based on expression of PD-L1, PD-1, peritumoral
CD8+ tumor infiltrating lymphocytes (TILs), peritumoral CD4+ TILs, and regulatory T cells as
analyzed from tumor biopsies in previously treated patients with metastatic SCCA of the anal
canal when treated with nivolumab plus or minus ipilimumab. (Part B) IV. To evaluate
radiographic responses according to relative changes in proportions of anti-HPV specific CD8+
and CD4+ TILs and regulatory T cells in patients with previously treated metastatic SCCA of
the anal canal following treatment with nivolumab plus or minus ipilimumab. (Part B)

OUTLINE:

PART A: Patients receive nivolumab intravenously (IV) over 60 minutes once every two weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity.

PART B: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues
in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30
minutes once every 8 weeks. Treatment continues in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up for 100 days and then every 3
months for 2 years.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed previously treated
metastatic squamous cell carcinoma of the anal canal

- Patients must have measurable disease according to the standard Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1, computed tomography (CT) scans or
magnetic resonance imaging (MRI)s used to assess the measurable disease must have been
completed within 28 days prior to study drug initiation

- Patients must have been treated with at least one prior systemic treatment for
incurable advanced or metastatic SCCA of the anal canal; prior treatment for
metastatic disease is not required for patients who develop new metastatic lesions
during or within 6 months of completion of chemoradiation for limited-stage disease;
patients who receive chemotherapy for incurable advanced or metastatic SCCA of the
anal canal must wait a minimum >= 28 days (6 weeks for nitrosoureas or mitomycin C)
after the date of completion of chemotherapy prior to initiating treatment with
nivolumab on this study; patients who undergo palliative radiotherapy to a site of
tumor must wait a minimum >= 28 days from the date of completion of radiotherapy prior
to initiating treatment with nivolumab (Part A and B) or nivolumab +/- Ipilimumab
(Part B) on this study

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 80%)

- Leukocytes >= 2,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Hemoglobin >= 9.0 gm/dL

- Platelets >= 100,000/mcL

- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients
with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 x ULN

- Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using
the Cockcroft-Gault formula)

- Before study enrollment, women of child bearing potential must be advised of the
importance of avoiding pregnancy during study participation and the potential risk
factors for an unintentional pregnancy; the subject must sign an informed consent form
documenting this discussion; women of child-bearing potential (WOCBP) and men must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation; women of
childbearing potential MUST have a negative serum or urine pregnancy test (minimum
sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within
24 hours prior to the start of nivolumab with or without ipilimumab; the minimum
sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG; if the
pregnancy test is positive, the subject must not receive nivolumab with or without
ipilimumab and must not be enrolled in the study

- Women of childbearing potential (WOCBP) is defined as any female who has experienced
menarche and who has not undergone surgical sterilization (hysterectomy or bilateral
oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12
months of amenorrhea in a woman over 45 in the absence of other biological or
physiological causes

- WOCBP receiving nivolumab (Parts A+B) or nivolumab and ipilimumab (Part B) will be
instructed to adhere to contraception for a period of 5 months after the last dose of
investigational product; men receiving nivolumab (Parts A+B) or nivolumab and
ipilimumab (Part B only) and who are sexually active with WOCBP will be instructed to
adhere to contraception for a period of 7 months after the last dose of
investigational product; these durations have been calculated using the upper limit of
the half-life for nivolumab (25 days) and are based on the protocol requirement that
WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active
with WOCBP use contraception for 5 half-lives plus 90 days

- Should a woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she (or the participating partner) should inform the
treating physician immediately; if, following initiation of the investigational
product, it is subsequently discovered that a study subject is pregnant or may have
been pregnant at the time of investigational product exposure, including during at
least 6 half-lives after product administration, the investigational product will be
permanently discontinued in an appropriate manner (e.g., dose tapering if necessary
for subject safety); the investigator must immediately notify BMS of this event and
record the pregnancy on the Pregnancy Surveillance Form (not an severe adverse event
[SAE] form); initial information on a pregnancy must be reported immediately to BMS,
and the outcome information provided once the outcome is known; completed Pregnancy
Surveillance Forms must be forwarded to BMS according to SAE reporting procedures; any
pregnancy that occurs in a female partner of a male study participant should be
reported to the sponsor. Information on this pregnancy will be collected on the
Pregnancy Surveillance Form; protocol-required procedures for study discontinuation
and follow-up must be performed on the subject unless contraindicated by pregnancy
(e.g., X-ray studies); other appropriate pregnancy follow-up procedures should be
considered if indicated. In addition, the investigator must report and follow-up on
information regarding the course of the pregnancy, including perinatal and neonatal
outcome. Infants should be followed for a minimum of 8 weeks

- Ability to understand and the willingness to sign a written informed consent document

- Brain metastases are allowed if they have been adequately treated with radiotherapy or
surgery and have been stable for at least three months prior to registration; eligible
subjects should be neurologically asymptomatic; there is no magnetic resonance imaging
(MRI) evidence of progression for a minimum of 4 weeks after treatment is complete and
within 28 days prior to the first dose of nivolumab administration; there must also be
no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day
prednisone equivalents) for at least 2 weeks prior to study drug administration

- Willingness for evaluation of cardiac function including electrocardiography (EKG) and
echocardiogram (ECHO) cardiogram for any patients with a history of congestive heart
failure (CHF) or at risk because of underlying cardiovascular disease or exposure to
cardiotoxic drugs as clinically indicated

- All patients must be willing to undergo testing for human immunodeficiency virus (HIV)
testing if not tested within the past 6 months

- If HIV+ positive, all patients infected with human immunodeficiency virus (HIV) may be
eligible for study provided that their CD4+ count >= 300/uL; their viral load is
undetectable; they are currently receiving highly active antiretroviral therapy
(HAART)

- All HIV+ patients will be under the care of an infectious diseases specialist; if a
relationship with an infectious diseases specialist is not established, infectious
disease specialist will be consulted; records of all viral counts and peripheral
T-cell counts must be sent to the study coordinator in order to follow these values
over the course of treatment

- All patients must be willing to be tested for hepatitis screening; patients
co-infected with hepatitis B virus and/or hepatitis C virus may be included in this
study provided that their liver function tests remain within the limits listed above;
patients must be followed by a hepatologist during the course of this study

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events (AEs) due to agents administered more than 4 weeks
earlier (i.e., grade >= 2 AE present); palliative (limited-field) radiation therapy is
permitted, as long as the lesion being considered for palliative radiation is not a
target lesion

- Patients who are receiving any other investigational agents

- Patients should be excluded if they have had prior treatment with an anti-PD-1,
anti-PD-L1, anti-programmed cell death ligand 2 (PD-L2), anti-cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug
specifically targeting T-cell co-stimulation or immune checkpoint pathways

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to nivolumab (Parts A+ B) and/or ipilimumab (Part B)

- History of severe hypersensitivity reaction to any monoclonal antibody

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Patients with active autoimmune disease or history of autoimmune disease that might
recur, which may affect vital organ function or require immune suppressive treatment
including chronic prolonged systemic corticosteroids (defined as corticosteroid use of
duration one month or greater), should be excluded; these include but are not limited
to patients with a history of immune related neurologic disease, multiple sclerosis,
autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis;
systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective
tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative
colitis, and patients with a history of toxic epidermal necrolysis (TEN),
Stevens-Johnson syndrome, or anti-phospholipid syndrome should be excluded

- Patients should be excluded if they have a condition requiring systemic treatment with
either corticosteroids (> 10 mg daily prednisone equivalents) or other
immunosuppressive medications within 14 days of study drug administration; inhaled or
topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents
are permitted in the absence of active autoimmune disease; patients are permitted to
use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids
(with minimal systemic absorption); physiologic replacement doses of systemic
corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief
course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for
treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction
caused by contact allergen) is permitted

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for at least three years
We found this trial at
42
sites
Fairfield, Connecticut 06824
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Fairfield, CT
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Patrick M. Boland
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: John C. Krauss
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Christopher H. Lieu
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Blase N. Polite
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: John L. Hays
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Principal Investigator: Manik A. Amin
Phone: 800-600-3606
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Syed M. Kazmi
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
5201 Harry Hines Blvd
Dallas, Texas 75235
(214) 590-8000
Principal Investigator: Syed M. Kazmi
Phone: 214-590-5582
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Derby, Connecticut 06418
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Derby, CT
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Anthony F. Shields
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: James L. Abbruzzese
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
Principal Investigator: Anthony F. Shields
Phone: 313-576-9790
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Syed M. Kazmi
Phone: 214-648-7097
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
111 Goose Lane
Guilford, Connecticut 06437
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Guilford, CT
Click here to add this to my saved trials
Hartford, Connecticut 06105
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Hartford, CT
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Cathy Eng
Phone: 877-312-3961
?
mi
from
Houston, TX
Click here to add this to my saved trials
1983 Marengo St
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Syma Iqbal
Phone: 323-865-0451
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Syma Iqbal
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Kristen K. Ciombor
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Howard S. Hochster
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Haven, Connecticut 06510
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Lenox, Illinois 60451
Principal Investigator: Blase N. Polite
Phone: 773-702-8222
?
mi
from
New Lenox, IL
Click here to add this to my saved trials
North Haven, Connecticut 06473
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
North Haven, CT
Click here to add this to my saved trials
Orland Park, Illinois 60462
Principal Investigator: Blase N. Polite
Phone: 773-702-8222
?
mi
from
Orland Park, IL
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Manik A. Amin
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Louis, Missouri 63129
Principal Investigator: Manik A. Amin
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
11155 Dunn Road
Saint Louis, Missouri 63136
Principal Investigator: Manik A. Amin
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
150 Entranceway Drive
Saint Peters, Missouri 63376
Principal Investigator: Manik A. Amin
Phone: 800-600-3606
?
mi
from
Saint Peters, MO
Click here to add this to my saved trials
801 N Rutledge St
Springfield, Illinois 62702
(217) 545-8000
Southern Illinois University School of Medicine At SIU School of Medicine, research includes biologically oriented...
?
mi
from
Springfield, IL
Click here to add this to my saved trials
?
mi
from
Toronto,
Click here to add this to my saved trials
200 Kennedy Drive
Torrington, Connecticut 06790
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Torrington, CT
Click here to add this to my saved trials
Trumbull, Connecticut 06611
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Trumbull, CT
Click here to add this to my saved trials
Washington, District of Columbia 20007
Principal Investigator: Michael J. Pishvaian
Phone: 202-444-2223
?
mi
from
Washington,
Click here to add this to my saved trials
Waterbury, Connecticut 06708
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Waterbury, CT
Click here to add this to my saved trials
Waterford, Connecticut 06385
Principal Investigator: Khanh T. Nguyen
Phone: 203-785-5702
?
mi
from
Waterford, CT
Click here to add this to my saved trials